Stark County teen’s stem cell treatment ‘going in the right direction’ – Peoria Journal Star
Peoria Journal Star |
Stark County teen’s stem cell treatment ‘going in the right direction’
Peoria Journal Star TOULON — A large benefit auction and dinner Friday evening will raise funds to help cover medical expenses for a Stark County teenager who is undergoing experimental stem cell treatment for a debilitating autoimmune disorder. Proceeds of the event to … |
Oncology Nurse Advisor |
Autologous T–Cell Therapy Promising in Advanced Sarcoma
Oncology Nurse Advisor CHICAGO — Infusion of autologous HER2-CAR T cells after lymphodepletion is safe and appears to be associated with objective clinical benefit in patients with advanced HER2+ sarcoma, according to the findings of a small phase I study presented at the … |
Medical Daily |
Immunotherapy drug effective for metastatic triple negative breast cancer
Science Daily The immunotherapy drug pembrolizumab — already FDA-approved for other forms of cancer-has been found to be effective in patients with metastatic triple negative breast cancer, according to an international clinical trial led by NYU Langone’s … Treatment For Triple Negative Breast Cancer; Immunotherapy Drug …Medical Daily |
|
Next-generation sequencing test identifies pathogens quickly in stem cell transplant patients
Healio NEW ORLEANS — A novel, next-generation sequencing plasma assay identified a broad range of infections more quickly than conventional tests in stem cell transplant patients, researchers said. |
|
CAR T-cell immunotherapy prompts durable response for ALL
Healio CHICAGO — Young patients with extramedullary relapse of acute lymphoblastic leukemia achieved potent and durable responses to single-agent chimeric antigen receptor T-cell immunotherapy, according to data presented at the ASCO Annual Meeting. |
|
Saturday at ASCO: promising immunotherapy combination data, but no home runs
Medical Marketing and Media As thousands of people descended upon Chicago this weekend for the American Society of Clinical Oncology’s annual meeting, some of the most pressing questions focused on how clinical trials treating non-small cell lung cancer with immunotherapy … |